A clinical study with BrainCool products has been published in JCM (impact factor 3.9) by researchers at the Center for Cardiac Arrest Research at Karolinska Institute (Ref 1). The study evaluated the RhinoChill® System to initiate early cooling treatment immediately after arrival at the hospital instead of waiting until patients arrived in the intensive care unit.
The research group at Karolinska Institute has shown for the first time that it is possible that RhinoChill®, as the only method on the market, can deliver effective and continuous cooling that can be started in the emergency department and continue during transport to and in connection with X-rays and advanced heart examinations.
When patients arrived in the intensive care unit, the BrainCool™ System was used for systemic cooling for 24 hours.
Karolinska Institute, with support from BrainCool AB, is also running the European multicenter study PRINCESS2 to study ultra-early cooling with RhinoChill® in patients who suffer cardiac arrest outside the hospital.
1. JCM | Free Full-Text | Transnasal Evaporative Cooling in Out-of-Hospital Cardiac Arrest Patients to Initiate Hypothermia—A Substudy of the Target Temperature Management 2 (TTM2) Randomized Trial (mdpi.com)
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.